Jonathan Richard White, Saqib Ahmad, Fahad Ashraf, Stephen Foley, Said Din, R. Das, Nina Mary Charles, João Pinheiro, Altaf Palejwala, Pamela Wright, Manoharan Andiappan, Myriam Alexander, Burhan Uddin, D. Hoshen, David A Elphick, Tufail Qamar, Nivin Rezwan, Mohammad Viquaruddin Hamza, John Glover, R. Robinson, Veena Gopakumar, A. Sajjad, Muhammad Shahzad, Gordon Moran
{"title":"英国东米德兰地区乌司替尼治疗克罗恩病的实际临床效果","authors":"Jonathan Richard White, Saqib Ahmad, Fahad Ashraf, Stephen Foley, Said Din, R. Das, Nina Mary Charles, João Pinheiro, Altaf Palejwala, Pamela Wright, Manoharan Andiappan, Myriam Alexander, Burhan Uddin, D. Hoshen, David A Elphick, Tufail Qamar, Nivin Rezwan, Mohammad Viquaruddin Hamza, John Glover, R. Robinson, Veena Gopakumar, A. Sajjad, Muhammad Shahzad, Gordon Moran","doi":"10.1136/flgastro-2024-102718","DOIUrl":null,"url":null,"abstract":"To evaluate the effectiveness of ustekinumab in treating Crohn’s disease (CD) in a UK real-world setting.This was a multicentre, retrospective observational study of patients (aged ≥18 years) with CD or inflammatory bowel disease of unclassified type (IBDU) starting ustekinumab between 11 November 2016 and 1 August 2020 across eight English hospitals. The primary objective was to determine the proportion of patients achieving corticosteroid-free remission at week 52 for patients with CD/IBDU following initiation with ustekinumab. Corticosteroid-free remission was defined as achieving a clinical Harvey-Bradshaw Index (HBI) score of ≤4 and corticosteroid-free status.The analysis included 422 patients with CD/IBDU. Corticosteroid-free remission was 41% (68/166) at week 16, 41% (47/115) at week 30 and 48% (38/80) at week 52. Clinical remission was 51% (85/166) at week 16 and 50% (40/80) at week 52. Clinical response was 34% (43/125) at week 16 and 32% (17/53) at week 52. Objective remission was 40% (4/10) at week 16 and 70% (7/10) at week 52. Corticosteroid-free remission at week 52 was achieved in patients with previous exposure to 1–2 biologics and/or small oral molecules (56%; 35/63), those without surgical history (64%; 16/25), and those without penetrating disease (54%; 29/54). Patients who achieved clinical remission at week 16 were more likely to achieve corticosteroid-free remission at week 52 (70%; 14/20) versus those who did not (20%; 4/20). In total, 37 adverse events occurred in 21 patients.This multicentre study provides real-world experience of ustekinumab in patients with CD/IBDU in England.","PeriodicalId":46937,"journal":{"name":"Frontline Gastroenterology","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real-world clinical effectiveness of ustekinumab in the treatment of Crohn’s disease in the East Midlands UK\",\"authors\":\"Jonathan Richard White, Saqib Ahmad, Fahad Ashraf, Stephen Foley, Said Din, R. Das, Nina Mary Charles, João Pinheiro, Altaf Palejwala, Pamela Wright, Manoharan Andiappan, Myriam Alexander, Burhan Uddin, D. Hoshen, David A Elphick, Tufail Qamar, Nivin Rezwan, Mohammad Viquaruddin Hamza, John Glover, R. Robinson, Veena Gopakumar, A. Sajjad, Muhammad Shahzad, Gordon Moran\",\"doi\":\"10.1136/flgastro-2024-102718\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"To evaluate the effectiveness of ustekinumab in treating Crohn’s disease (CD) in a UK real-world setting.This was a multicentre, retrospective observational study of patients (aged ≥18 years) with CD or inflammatory bowel disease of unclassified type (IBDU) starting ustekinumab between 11 November 2016 and 1 August 2020 across eight English hospitals. The primary objective was to determine the proportion of patients achieving corticosteroid-free remission at week 52 for patients with CD/IBDU following initiation with ustekinumab. Corticosteroid-free remission was defined as achieving a clinical Harvey-Bradshaw Index (HBI) score of ≤4 and corticosteroid-free status.The analysis included 422 patients with CD/IBDU. Corticosteroid-free remission was 41% (68/166) at week 16, 41% (47/115) at week 30 and 48% (38/80) at week 52. Clinical remission was 51% (85/166) at week 16 and 50% (40/80) at week 52. Clinical response was 34% (43/125) at week 16 and 32% (17/53) at week 52. Objective remission was 40% (4/10) at week 16 and 70% (7/10) at week 52. Corticosteroid-free remission at week 52 was achieved in patients with previous exposure to 1–2 biologics and/or small oral molecules (56%; 35/63), those without surgical history (64%; 16/25), and those without penetrating disease (54%; 29/54). Patients who achieved clinical remission at week 16 were more likely to achieve corticosteroid-free remission at week 52 (70%; 14/20) versus those who did not (20%; 4/20). In total, 37 adverse events occurred in 21 patients.This multicentre study provides real-world experience of ustekinumab in patients with CD/IBDU in England.\",\"PeriodicalId\":46937,\"journal\":{\"name\":\"Frontline Gastroenterology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-06-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontline Gastroenterology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/flgastro-2024-102718\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontline Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/flgastro-2024-102718","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
Real-world clinical effectiveness of ustekinumab in the treatment of Crohn’s disease in the East Midlands UK
To evaluate the effectiveness of ustekinumab in treating Crohn’s disease (CD) in a UK real-world setting.This was a multicentre, retrospective observational study of patients (aged ≥18 years) with CD or inflammatory bowel disease of unclassified type (IBDU) starting ustekinumab between 11 November 2016 and 1 August 2020 across eight English hospitals. The primary objective was to determine the proportion of patients achieving corticosteroid-free remission at week 52 for patients with CD/IBDU following initiation with ustekinumab. Corticosteroid-free remission was defined as achieving a clinical Harvey-Bradshaw Index (HBI) score of ≤4 and corticosteroid-free status.The analysis included 422 patients with CD/IBDU. Corticosteroid-free remission was 41% (68/166) at week 16, 41% (47/115) at week 30 and 48% (38/80) at week 52. Clinical remission was 51% (85/166) at week 16 and 50% (40/80) at week 52. Clinical response was 34% (43/125) at week 16 and 32% (17/53) at week 52. Objective remission was 40% (4/10) at week 16 and 70% (7/10) at week 52. Corticosteroid-free remission at week 52 was achieved in patients with previous exposure to 1–2 biologics and/or small oral molecules (56%; 35/63), those without surgical history (64%; 16/25), and those without penetrating disease (54%; 29/54). Patients who achieved clinical remission at week 16 were more likely to achieve corticosteroid-free remission at week 52 (70%; 14/20) versus those who did not (20%; 4/20). In total, 37 adverse events occurred in 21 patients.This multicentre study provides real-world experience of ustekinumab in patients with CD/IBDU in England.
期刊介绍:
Frontline Gastroenterology publishes articles that accelerate adoption of innovative and best practice in the fields of gastroenterology and hepatology. Frontline Gastroenterology is especially interested in articles on multidisciplinary research and care, focusing on both retrospective assessments of novel models of care as well as putative future directions of best practice. Specifically Frontline Gastroenterology publishes articles in the domains of clinical quality, patient experience, service provision and medical education.